ecancermedicalscience

Review

Current management approach to hidradenocarcinoma: a comprehensive review of the literature

19 Mar 2015
Abhishek Soni, Nupur Bansal, Vivek Kaushal, Ashok Kr Chauhan

Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials.

Related Articles

Seema Rajesh Rao, Mithili Narayan Sherigar, Michelle Normen, Udita Joshi
Eve Namisango, Tonia Onyeka, Nafula Esther, Emmanuel B K Luyirika, Zipporah Ali, Richard A Powell
Julia Downing, Alexandra Daniels, Michael J McNeil, Mariam Ndagire, Gayatri Palat, Justin N Baker, Rima S Rassam